Regeneron Reports 70% VGPR+ Efficacy for Lynozyfic in Multiple Myeloma
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 59 minutes ago0mins
- Clinical Trial Results: The LINKER-MM4 trial demonstrated that Lynozyfic achieved a ≥70% VGPR+ response rate in multiple myeloma patients, with expectations that these responses will deepen over time, thereby providing a more effective monotherapy option for patients.
- MRD Negativity Rate: Among all dose groups, 95% of VGPR+ patients achieved minimal residual disease (MRD) negative status, indicating Lynozyfic's potential in early treatment, which may simplify treatment regimens and enhance patient tolerability.
- Safety Profile: Of the 45 treated patients, the most common treatment-emergent adverse events included cytokine release syndrome (44%) and neutropenia (38%), demonstrating a favorable safety profile for Lynozyfic, with no ≥Grade 4 infections or dose-limiting toxicities reported.
- Future Development Plans: Regeneron is conducting a broad clinical development program to evaluate Lynozyfic's application in early-stage multiple myeloma treatment, further solidifying its market position in the hematologic cancer treatment landscape.
REGN.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is 742.00 USD with a low forecast of 627.00 USD and a high forecast of 870.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
16 Buy
5 Hold
1 Sell
Moderate Buy
Current: 722.800
Low
627.00
Averages
742.00
High
870.00
Current: 722.800
Low
627.00
Averages
742.00
High
870.00
BMO Capital
Evan Seigerman
Outperform
maintain
$725 -> $850
2025-12-04
New
Reason
BMO Capital
Evan Seigerman
Price Target
$725 -> $850
2025-12-04
New
maintain
Outperform
Reason
BMO Capital analyst Evan Seigerman raised the firm's price target on Regeneron to $850 from $725 and keeps an Outperform rating on the shares. Following Regeneron's itepekimab miss in June, shares have appreciated about 50% as efforts to resolve regulatory uncertainty have started to pay dividends, the analyst tells investors in a research note. BMO adds it is raising its target price as the firm expects higher contributions from Dupixent and more moderate erosion of 2mg Eylea than previously estimated.
Canaccord
Buy
maintain
$850
2025-12-04
New
Reason
Canaccord
Price Target
$850
2025-12-04
New
maintain
Buy
Reason
Canaccord raised the firm's price target on Regeneron to $1,057 from $850 and keeps a Buy rating on the shares. The firm said they expect Dupixent growth to continue to outpace EYLEA revenues, providing upside going forward. Sanofi collaboration revenue surpassed US EYLEA revenues for the first time in 1Q25, and the gap should continue to widen. As EYLEA sales continue to decline, they see Dupixent as the key growth driver going forward.
Morgan Stanley
Overweight -> Equal Weight
downgrade
$767
2025-12-03
New
Reason
Morgan Stanley
Price Target
$767
2025-12-03
New
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley downgraded Regeneron to Equal Weight from Overweight with an unchanged price target of $767. The firm sees a balanced risk/reward pending further visibility on the company's pipeline diversification. Regeneron shares have rebounded off the lows earlier this year following progress with Eylea, the analyst tells investors in a research note. Morgan Stanley cites valuation for the downgrade.
Scotiabank
Sector Perform
maintain
$650 -> $770
2025-11-24
Reason
Scotiabank
Price Target
$650 -> $770
2025-11-24
maintain
Sector Perform
Reason
Scotiabank raised the firm's price target on Regeneron to $770 from $650 and keeps a Sector Perform rating on the shares. The firm is raising its price target on the stock due to "solid" execution as well as "positive vibes" following the recent upside surprise on Eylea HD approvals and ahead of 2026 data readouts, the analyst tells investors.
See All Ratings
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What factors contributed to Regeneron's 36% share price surge last month?
How does Dupixent's EU approval impact Regeneron's market positioning?
Will Eylea HD's FDA approval lead to significant revenue growth for Regeneron?
Can Dupixent's success in treating CSU drive long-term revenue for Regeneron?